News
Sixty seconds on . . . Zavicefta
BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1409 (Published 22 March 2017) Cite this as: BMJ 2017;356:j1409
- Nigel Hawkes
- London
A new antibiotic? That’s good news
It is. Growing antimicrobial resistance is a serious threat, so any evidence that the drug industry is focusing on new antibiotics is cheering.
The headlines say that it will tackle resistance
That’s the claim. Zavicefta combines an established antibiotic, ceftazidime, with a second component, avibactam, designed to inhibit one of the pathways by which antibiotics acquire resistance.
Is this new?
No. Beta lactamase inhibitors …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.